RayKnowChina Research Map
Shortlist0

RecruitingHaemophagocytic lymphohistiocytosisPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

An open trial on haemophagocytic lymphohistiocytosis, registered on ClinicalTrials.gov. Led by Beijing Tongren Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07525466, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed extranodal NK/T-cell lymphoma.

    Inclusion criterion 1

  3. Female patients who are pregnant or breastfeeding;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07525466, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically confirmed extranodal NK/T-cell lymphoma.
  • Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria).
  • Age ≥ 18 years, regardless of gender.
  • Negative HIV antigen or antibody.
  • Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac echocardiography.
  • No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral).
  • No uncontrolled infection (e.g., pulmonary infection, intestinal infection).
  • Negative HCV antibody; or positive HCV antibody with negative HCV RNA.
  • Negative HBsAg and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be < 1×10³ copies/mL to be eligible.
  • Signed written informed consent and ability to understand and comply with all study requirements.

Exclusion Criteria:

  • New York Heart Association (NYHA) cardiac function class ≥ II;
  • Female patients who are pregnant or breastfeeding;
  • Known hypersensitivity to any of the study drugs;
  • Presence of other concurrent malignancies (except non-melanoma skin cancer);
  • Concurrent central nervous system lymphoma infiltration;
  • Severe psychiatric disorders or inability to comply with follow-up;
  • Severe renal dysfunction (glomerular filtration rate < 15 mL/min);
  • Severe liver cirrhosis (MELD score > 20);
  • History of acute or chronic pancreatitis;
  • Simultaneous participation in another clinical trial.

Quoted from ClinicalTrials.gov, NCT07525466, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07525466, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07525466